Cell & Gene Therapy Investment Report - Q3

Phacilitate’s latest investment report explores where funding flowed in Q3 2026, from early-stage grants to major strategic acquisitions, and what the data reveals about shifting investor priorities across the sector.

What’s inside:

• A breakdown of cell and gene therapy investment by funding round, including total capital raised and deal activity
• The top 5 cell therapy transactions
• The most active investors across both sectors, ranked by deal participation
• Insights into where capital is concentrating, from early stage-innovation to larger, later-stage financing rounds

*Data sourced and verified by Byte51.